Keeling et al. (14) showed in the mucopolysaccharidosis I-Hurler mouse model, co-administration of the NMD specific inhibitor, NMDI-1, together with gentamicin increased enzyme activity compared to gentamicin alone. Here, PLA1A is linked to mucopolysaccharidosis type 1.